Key facts
- This page summarizes Donald R. Wilson Jr.'s Form 4 filing for Aptose Biosciences Inc. (APTOF).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Aug 2021, 21:54.
Donald R. Wilson Jr. - 03 Aug 2021 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- APTOF
- Reported as of
- 03 Aug 2021
- Net transaction value
- -$5,794
- Reporting owner signature
- /s/ Donald R. Wilson, Jr.
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Donald R. Wilson Jr. filed Form 4 for Aptose Biosciences Inc. (APTOF) on 05 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$5,794.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APTO
transaction
Common Stock
Purchase
- Transaction value
- $151,406
- Shares
- +57,199
- Change %
- +0.64%
- Price
- $2.65
- Shares after
- 8,948,275
- Date
- 03 Aug 2021
- Ownership
- Through DRW Investments, LLC
- Footnotes
- F1, F2, F3
APTO
transaction
Common Stock
Sale
- Transaction value
- $157,200
- Shares
- -60,000
- Change %
- -0.67%
- Price
- $2.62
- Shares after
- 8,888,275
- Date
- 05 Aug 2021
- Ownership
- Through DRW Investments, LLC
- Footnotes
- F3
APTO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,162
- Date
- 03 Aug 2021
- Ownership
- Through DRW Commodities, LLC
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Donald R. Wilson Jr. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.64 to $2.65, inclusive. The Reporting Persons (as defined below) undertake to provide to Aptose Biosciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F2
This Form 4 is being filed by the undersigned Donald R. Wilson Jr. ("Wilson"), as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Wilson is the sole manager of each of DRW Investments, LLC ("DRW Investments"), DRW Commodities, LLC ("DRW Commodities") and DRW Holdings, LLC ("DRW Holdings"). DRW Holdings owns 100% of the outstanding equity of each of DRW Commodities and DRW Investments. A majority of the equity of DRW Holdings is owned, directly or indirectly, by trusts for the benefit of members of Wilson's immediate family and of which Wilson serves as trustee or investment advisor.
Footnote F3
Each of the Reporting Persons disclaims beneficial ownership of any securities held by DRW Commodities or DRW Investments, except to the extent of his indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.